Literature DB >> 25941547

Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors.

Song Feng1, Di Hong1, Baoxia Wang1, Xiufang Zheng1, Kun Miao1, Lisha Wang1, Hongying Yun1, Lu Gao1, Shuhai Zhao1, Hong C Shen1.   

Abstract

A series of imidazolepyridine derivatives were designed and synthesized according to the established docking studies. The imidazopyridine derivatives were found to have good potency and physical-chemical properties. Several highly potent compounds such as 8ji, 8jl, and 8jm were identified with single nanomolar activities. The most potent compound 8jm showed an IC50 of 3 nM, lower microsome clearance and no CYP inhibition. The profile of 8jm appeared to be superior to BMS433771, and supported further optimization.

Entities:  

Keywords:  Respiratory syncytial virus (RSV); antiviral; fusion inhibitors; heterocycle; imidazopyridine; virus

Year:  2015        PMID： 25941547      PMCID： PMC4416423          DOI： 10.1021/acsmedchemlett.5b00008

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  23 in total

Review 1.  The structural biology of type I viral membrane fusion.

Authors:  Peter M Colman; Michael C Lawrence
Journal:  Nat Rev Mol Cell Biol       Date:  2003-04       Impact factor: 94.444

Review 2.  The pathogenesis of measles.

Authors:  Rory D de Vries; Annelies W Mesman; Teunis B H Geijtenbeek; W Paul Duprex; Rik L de Swart
Journal:  Curr Opin Virol       Date:  2012-04-05       Impact factor: 7.090

Review 3.  Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection.

Authors:  Jean-François Bonfanti; Dirk Roymans
Journal:  Curr Opin Drug Discov Devel       Date:  2009-07

4.  HIV-1 inhibition by a peptide.

Authors:  S Jiang; K Lin; N Strick; A R Neurath
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

Review 5.  Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor.

Authors:  Christopher Cianci; Nicholas Meanwell; Mark Krystal
Journal:  J Antimicrob Chemother       Date:  2005-01-28       Impact factor: 5.790

6.  Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein.

Authors:  Janet L Douglas; Marites L Panis; Edmund Ho; Kuei-Ying Lin; Steve H Krawczyk; Deborah M Grant; Ruby Cai; Swami Swaminathan; Tomas Cihlar
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Respiratory syncytial virus fusion inhibitors. Part 6: an examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety.

Authors:  Keith D Combrink; H Belgin Gulgeze; Jan W Thuring; Kuo-Long Yu; Rita L Civiello; Yi Zhang; Bradley C Pearce; Zhiwei Yin; David R Langley; Kathleen F Kadow; Christopher W Cianci; Zhufang Li; Junius Clarke; Eugene V Genovesi; Ivette Medina; Lucinda Lamb; Zheng Yang; Lisa Zadjura; Mark Krystal; Nicholas A Meanwell
Journal:  Bioorg Med Chem Lett       Date:  2007-06-26       Impact factor: 2.823

8.  Orally active fusion inhibitor of respiratory syncytial virus.

Authors:  Christopher Cianci; Kuo-Long Yu; Keith Combrink; Ny Sin; Bradley Pearce; Alan Wang; Rita Civiello; Stacey Voss; Guangxiang Luo; Kathy Kadow; Eugene V Genovesi; Brian Venables; Hatice Gulgeze; Ashok Trehan; Jennifer James; Lucinda Lamb; Ivette Medina; Julia Roach; Zheng Yang; Lisa Zadjura; Richard Colonno; Junius Clark; Nicholas Meanwell; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.

Authors:  Parthiv J Mahadevia; Anthony S Masaquel; Mark J Polak; Leonard B Weiner
Journal:  J Med Econ       Date:  2012-05-10       Impact factor: 2.448

10.  A prospective three-year cohort study of the epidemiology and virology of acute respiratory infections of children in rural India.

Authors:  Shobha Broor; Shama Parveen; Preeti Bharaj; Velisetty S Prasad; Kavalu N Srinivasulu; Krishna M Sumanth; Suresh Kumar Kapoor; Karen Fowler; Wayne M Sullender
Journal:  PLoS One       Date:  2007-06-06       Impact factor: 3.240
View more
  11 in total

1.  Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins.

Authors:  Toru Yamaguchi-Sasaki; Seiken Tokura; Yuya Ogata; Takanori Kawaguchi; Yutaka Sugaya; Ryo Takahashi; Kanako Iwakiri; Tomoko Abe-Kumasaka; Ippei Yoshida; Kaho Arikawa; Hiroyuki Sugiyama; Kosuke Kanuma
Journal:  ACS Med Chem Lett       Date:  2020-04-10       Impact factor: 4.345

2.  Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors.

Authors:  Xiufang Zheng; Lisha Wang; Baoxia Wang; Kun Miao; Kunlun Xiang; Song Feng; Lu Gao; Hong C Shen; Hongying Yun
Journal:  ACS Med Chem Lett       Date:  2016-04-20       Impact factor: 4.345

3.  Discovery of (aza)indole derivatives as novel respiratory syncytial virus fusion inhibitors.

Authors:  Xiufang Zheng; Chungen Liang; Lisha Wang; Kun Miao; Baoxia Wang; Weixing Zhang; Dongdong Chen; Guolong Wu; Wei Zhu; Lei Guo; Song Feng; Lu Gao; Hong C Shen; Hongying Yun
Journal:  Medchemcomm       Date:  2019-05-06       Impact factor: 3.597

4.  Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection.

Authors:  Weihua Shi; Zhigan Jiang; Haiying He; Fubiao Xiao; Fusen Lin; Ya Sun; Lijuan Hou; Liang Shen; Lixia Han; Minggao Zeng; Kunmin Lai; Zhengxian Gu; Xinsheng Chen; Tao Zhao; Li Guo; Chun Yang; Jian Li; Shuhui Chen
Journal:  ACS Med Chem Lett       Date:  2018-01-10       Impact factor: 4.345

5.  Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts.

Authors:  Naresh Gunaganti; Anupreet Kharbanda; Naga Rajiv Lakkaniga; Lingtian Zhang; Rose Cooper; Hong-Yu Li; Brendan Frett
Journal:  Chem Commun (Camb)       Date:  2018-11-15       Impact factor: 6.222

6.  Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses.

Authors:  Jimin Xu; Wenzhe Wu; Haiying Chen; Yu Xue; Xiaoyong Bao; Jia Zhou
Journal:  Bioorg Med Chem       Date:  2021-04-18       Impact factor: 3.461

7.  Computational Breakthrough of Natural Lead Hits from the Genus of Arisaema against Human Respiratory Syncytial Virus.

Authors:  Kamal Kant; Uma Ranjan Lal; Manik Ghosh
Journal:  Pharmacogn Mag       Date:  2018-01-31       Impact factor: 1.085

8.  In silico virtual screening of lead compounds for major antigenic sites in respiratory syncytial virus fusion protein.

Authors:  Shilu Mathew; Sara Taleb; Ali Hussein Eid; Asmaa A Althani; Hadi M Yassine
Journal:  Emergent Mater       Date:  2021-05-03

Review 9.  Recent Progress in Metal-Free Direct Synthesis of Imidazo[1,2-a]pyridines.

Authors:  Vanya Kurteva
Journal:  ACS Omega       Date:  2021-12-14

10.  Discovery of New Potent anti-MERS CoV Fusion Inhibitors.

Authors:  Mahmoud Kandeel; Mizuki Yamamoto; Byoung Kwon Park; Abdulla Al-Taher; Aya Watanabe; Jin Gohda; Yasushi Kawaguchi; Kentaro Oh-Hashi; Hyung-Joo Kwon; Jun-Ichiro Inoue
Journal:  Front Pharmacol       Date:  2021-06-02       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.